Metabolomic Analysis Reveals Metabolic Disturbance in the Cortex and Hippocampus of Subchronic MK-801 Treated Rats

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Sun, Liya ^a,b   Li, Juan ^c,e   Zhou, Kejun ^a,b   Zhang, Ming ^a,b   Yang, Jinglei ^a,b   Li, Yang ^a,b   Ji, Baohu ^a,b   Zhang, Zhao ^a,b   Zhu, Hui ^a,b   Yang, Lun ^a,b   He, Guang ^a,b   Gao, Linghan ^a,b   Wei, Zhiyun ^a,b   Wang, Kejian ^a,b   Han, Xue ^d   Liu, Weiqing ^d   Tan, Liwen ^d   Yu, Yihua ^c   He, Lin ^a,b   Wan, Chunling ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c EAST CHINA NORMAL UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID; ALANINE; ASPARTIC ACID; CHOLINE; CITRIC ACID; CREATININE; DIZOCILPINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LACTIC ACID; PHOSPHORYLCHOLINE; SERINE; SUCCINIC ACID; TAURINE;

AMINO ACID BRAIN LEVEL; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; DOWN REGULATION; ENERGY METABOLISM; HIPPOCAMPUS; MALE; METABOLIC DISORDER; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN EXPRESSION; PROTEOMICS; RAT; SYNAPTOSOME;

ANIMALS; DIZOCILPINE MALEATE; ENERGY METABOLISM; GLUTAMIC ACID; HIPPOCAMPUS; HOMEOSTASIS; MALE; METABOLOMICS; NERVE NET; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 84875946194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060598     Document Type: Article

References (48)

1. Knapp M, Mangalore R, Simon J, (2004) The global costs of schizophrenia. Schizophr Bull 30: 279-293.
2. Rogers DP, Goldsmith CA, (2009) Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis. Expert Rev Neurother 9: 47-54.
3. Vita A, Dieci M, Giobbio GM, Tenconi F, Invernizzi G, (1997) Time course of cerebral ventricular enlargement in schizophrenia supports the hypothesis of its neurodevelopmental nature. Schizophr Res 23: 25-30.
4. Coyle JT, (2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26: 365-384.
5. Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C, (2008) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32: 1014-1023.
6. Rung JP, Carlsson A, Ryden Markinhuhta K, Carlsson ML, (2005) (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29: 827-832.
7. Zhou K, Yang Y, Gao L, He G, Li W, et al. (2010) NMDA Receptor Hypofunction Induces Dysfunctions of Energy Metabolism And Semaphorin Signaling in Rats: A Synaptic Proteome Study. Schizophr Bull.
8. Martins-de-Souza D, Harris LW, Guest PC, Bahn S, (2011) The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 15: 2067-2079.
9. Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U, (2006) Repeated injection of MK801: an animal model of schizophrenia? Neurochem Int 48: 541-546.
10. Eyjolfsson EM, Nilsen LH, Kondziella D, Brenner E, Haberg A, et al. (2010) Altered (13)C glucose metabolism in the cortico-striato-thalamo-cortical loop in the MK-801 rat model of schizophrenia. J Cereb Blood Flow Metab.
11. Kondziella D, Brenner E, Eyjolfsson EM, Markinhuhta KR, Carlsson ML, et al. (2006) Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure. Neuropsychopharmacology 31: 1880-1887.
12. Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U, (2007) How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Neurochem Int 50: 291-301.
13. Tsang TM, Griffin JL, Haselden J, Fish C, Holmes E, (2005) Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopy. Magn Reson Med 53: 1018-1024.
14. Fan TWM, (1996) Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. Progress in Nuclear Magnetic Resonance Spectroscopy 28: 161-219.
15. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, et al. (2005) High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem 280: 42508-42514.
16. Tsang TM, Haselden JN, Holmes E (2009) Metabonomic Characterization of the 3-Nitropropionic Acid Rat Model of Huntington's Disease. Neurochemical Research: 1-11.
17. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, et al. (2010) A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 56: 937-947.
18. Ting L, Cowley MJ, Hoon SL, Guilhaus M, Raftery MJ, et al. (2009) Normalization and statistical analysis of quantitative proteomics data generated by metabolic labeling. Mol Cell Proteomics 8: 2227-2242.
19. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B, (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379-382.
20. van Elst LT, Valerius G, Buchert M, Thiel T, Rusch N, et al. (2005) Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 58: 724-730.
21. Purdon SE, Valiakalayil A, Hanstock CC, Seres P, Tibbo P, (2008) Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr Res 99: 218-224.
22. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, et al. (2010) Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 15: 308-318.
23. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, et al. (2009) Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res 108: 69-77.
24. Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, et al. (2005) Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res 73: 153-157.
25. Loscher W, Honack D, Fassbender CP, (1991) Regional alterations in brain amino acids after administration of the N-methyl-D-aspartate receptor antagonists MK-801 and CGP 39551 in rats. Neurosci Lett 124: 115-118.
26. Brenner E, Kondziella D, Haberg A, Sonnewald U, (2005) Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801. J Neurochem 94: 1594-1603.
27. Zuo DY, Zhang YH, Cao Y, Wu CF, Tanaka M, et al. (2006) Effect of acute and chronic MK-801 administration on extracellular glutamate and ascorbic acid release in the prefrontal cortex of freely moving mice on line with open-field behavior. Life Sci 78: 2172-2178.
28. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, et al. (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160: 2231-2233.
29. Gonzalez-Burgos G, Lewis DA, (2008) GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34: 944-961.
30. Ongur D, Prescot AP, McCarthy J, Cohen BM, Renshaw PF, (2010) Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry 68: 667-670.
31. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, et al. (2002) The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 51: 377-386.
32. Xiao X, Dawson N, Macintyre L, Morris BJ, Pratt JA, et al. (2011) Exploring metabolic pathway disruption in the subchronic phencyclidine model of schizophrenia with the Generalized Singular Value Decomposition. BMC Syst Biol 5: 72.
33. Jenkins TA, Harte MK, Reynolds GP, (2010) Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Neurosci Lett 471: 144-147.
34. Reynolds GP, Beasley CL, (2001) GABAergic neuronal subtypes in the human frontal cortex-development and deficits in schizophrenia. J Chem Neuroanat 22: 95-100.
35. Meloni BP, Van Dyk D, Cole R, Knuckey NW, (2005) Proteome analysis of cortical neuronal cultures following cycloheximide, heat stress and MK801 preconditioning. Proteomics 5: 4743-4753.
36. Paulson L, Martin P, Nilsson CL, Ljung E, Westman-Brinkmalm A, et al. (2004) Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics 4: 819-825.
37. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P, (2002) Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22: 2718-2729.
38. Schousboe A, Sonnewald U, Waagepetersen HS, (2003) Differential roles of alanine in GABAergic and glutamatergic neurons. Neurochem Int 43: 311-315.
39. Waagepetersen HS, Sonnewald U, Larsson OM, Schousboe A, (2000) A possible role of alanine for ammonia transfer between astrocytes and glutamatergic neurons. J Neurochem 75: 471-479.
40. Ozeki Y, Pickard BS, Kano S, Malloy MP, Zeledon M, et al. (2011) A novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expression. Neurosci Res 69: 154-160.
41. Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, et al. (2008) Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 32: 1905-1912.
42. Ariyannur PS, Moffett JR, Manickam P, Pattabiraman N, Arun P, et al. (2010) Methamphetamine-induced neuronal protein NAT8L is the NAA biosynthetic enzyme: implications for specialized acetyl coenzyme A metabolism in the CNS. Brain Res 1335: 1-13.
43. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G, (2007) The kynurenic acid hypothesis of schizophrenia. Physiol Behav 92: 203-209.
44. Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, et al. (2006) Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 96: 1121-1129.
45. Sun Y, Savanenin A, Reddy PH, Liu YF, (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 276: 24713-24718.
46. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, et al. (2010) In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 19: 3053-3067.
47. Martins-de-Souza D, Harris LW, Guest PC, Bahn S, (2011) The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 15: 2067-2079.
48. Moghaddam B, Javitt D, (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37: 4-15.